Company profile: Marinomed Biotech
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies via patent-protected platforms, including MAVIREX-based products against respiratory viruses and the Marinosolv solubilization technology (available for partnerships via Solv4U). Portfolio includes Carragelose, Budesolv, Tacrosolv, and pipeline programs MAM-1004-2 (autoimmune gastritis) and MAM-1001-4 nasal spray.
Products and services
- Marinosolv®: A custom-engineered solubilization technology that enhances bioavailability of poorly soluble compounds, deployed in Marinomed’s products and accessible to external partners through Solv4U for formulation improvement
- Carragelose®: A medical-grade polymer from red seaweed that coats mucosal surfaces to prevent viral and allergen interaction with the mucosa, and delivers relief for dry eyes via a protective layer
- Budesolv: An industrial-grade nasal spray with budesonide solubilized via Marinosolv, intended to treat severe allergic rhinitis with faster onset of action and reduced therapeutic dose
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Marinomed Biotech
Coris BioConcept
HQ: Belgium
Website
- Description: Provider of rapid diagnostic kits, developing, marketing and selling assays including RESIST Range for antibiotic resistance (carbapenemase-producing organisms), Legionella K-SeT lateral flow test for Legionella pneumophila, HAT Sero K-SeT for Trypanosoma brucei gambiense, BL-RED electrochemical test for bacterial hydrolysis related to 3GC antibiotics, Giardia-Strip dipstick test, and RT-LAMP fluorescence assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coris BioConcept company profile →
Brii Biosciences
HQ: United States
Website
- Description: Provider of innovative medicines developed to improve public health in China, focusing on treatment options and preventive measures for Hepatitis B (prevention in Asia-Pacific excluding Japan), HIV therapies, NTM lung disease (Greater China rights), MDR/XDR Gram-negative bacterial infections (with Monash University), and anxiety and depressive disorders via internally discovered programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Brii Biosciences company profile →
Arbutus Biopharma
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies for hepatitis B virus (HBV), including Imdusiran (AB-729), a subcutaneously delivered RNAi therapeutic designed to reduce HBV viral antigens such as HBsAg, and AB-101, an oral PD-L1 inhibitor intended to reawaken HBV-specific T cells by blocking the PD-1/PD-L1 protein-protein interaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arbutus Biopharma company profile →
Trius Therapeutics
HQ: United States
Website
- Description: Provider of discovery, development and commercialization of innovative antibiotics for life-threatening infections. Completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI, with IV and orally administered formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trius Therapeutics company profile →
Discuva
HQ: United Kingdom
Website
- Description: Provider of next-generation antibiotic discovery, Cambridge (UK)-based, established to address major gaps in the treatment of infective disease using proprietary methods, and developer of Ivonescimab (SMT112), a bispecific PD-1/VEGF antibody for oncology in Phase III trials for non-small cell lung cancer and other solid tumors, with over 1,600 patients treated.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Discuva company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Marinomed Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Marinomed Biotech
2.2 - Growth funds investing in similar companies to Marinomed Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Marinomed Biotech
4.2 - Public trading comparable groups for Marinomed Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →